Literature DB >> 8617726

In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction.

G D Raffel1, K Parmar, N Rosenberg.   

Abstract

A necessary downstream element of Abelson murine leukemia virus (Ab-MLV)-mediated transformation is Ras, which can be activated by the phosphotyrosine-dependent association of Shc with the Grb2-mSos complex. Here we show that Shc is tyrosine-phosphorylated and associates with Grb2 in v-Abl-transformed cells, whereas Shc in NIH3T3 cells is phosphorylated solely on serine and is not Grb2-associated. In addition, Shc coprecipitates with P120 v-Abl and P70 v-Abl, which lacks the carboxyl terminus. Surprisingly, a kinase-defective mutant of P120 also binds Shc, demonstrating that Shc/v-Abl association is a phosphotyrosine-independent interaction. Glutathione S-transferase fusion proteins were used to map the interacting domains and showed that Shc from both NIH3T3 and v-Abl-transformed cells binds to the Abl SH2 domain and that P120 v-Abl binds to a region in the amino terminus of Shc. Consistent with these data, a v-Abl mutant encoding only the Gag and SH2 regions was able to bind Shc in vivo. The unique non-phosphotyrosine-mediated binding of Shc may allow direct tyrosine phosphorylation of Shc by v-Abl and subsequent activation of the Ras pathway through assembly of a signaling complex with Grb2-mSos.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617726     DOI: 10.1074/jbc.271.9.4640

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Na(+),K (+)-ATPase as a docking station: protein-protein complexes of the Na(+),K (+)-ATPase.

Authors:  Linda Reinhard; Henning Tidow; Michael J Clausen; Poul Nissen
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

2.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

3.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.

Authors:  Linda B Baughn; Naomi Rosenberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Characterization of a novel member of the DOK family that binds and modulates Abl signaling.

Authors:  F Cong; B Yuan; S P Goff
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

7.  Polyomavirus large T antigen induces alterations in cytoplasmic signalling pathways involving Shc activation.

Authors:  V Gottifredi; G Pelicci; E Munarriz; R Maione; P G Pelicci; P Amati
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Authors:  C A Mainville; K Parmar; I Unnikrishnan; L Gong; G D Raffel; N Rosenberg
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.

Authors:  T Pene-Dumitrescu; L F Peterson; N J Donato; T E Smithgall
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

10.  Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Authors:  Chae-ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.